Rezolute to Participate in Upcoming Investor Conferences
Globe Newswire•02/11/2026•07:30 ET
0
Key Highlights
- ➤Rezolute (RZLT) management to present at Guggenheim healthcare conference November 9
- ➤Rezolute management to present at Jefferies London Healthcare Conference November 19
- ➤Rezolute will hold one-on-one investor meetings during both conferences
- ➤Ersodetug has been studied for refractory hypoglycemia caused by hyperinsulinism
REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:
Event: Guggenheim 3(rd) Annual Healthcare Innovation Conference Date: November 9-11, 2026 Fireside Date/Time: Monday, November 9(th) at 9:00am ET
Get started
Create a free account to read the full story.